Last reviewed · How we verify
Comparator: placebo to sitagliptin
Comparator: placebo to sitagliptin is a DPP-4 inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Comparator: placebo to sitagliptin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sitagliptin is a DPP-4 inhibitor that prevents the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By extending the half-life of these hormones, sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning it primarily acts when blood glucose is elevated, reducing hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant (PHASE4)
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
- IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics (PHASE1)
- DPP4 Inhibition & Beta Cell Function (PHASE1)
- Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients (PHASE2)
- A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (PHASE1)
- DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function (PHASE3)
- Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: placebo to sitagliptin CI brief — competitive landscape report
- Comparator: placebo to sitagliptin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Comparator: placebo to sitagliptin
What is Comparator: placebo to sitagliptin?
How does Comparator: placebo to sitagliptin work?
What is Comparator: placebo to sitagliptin used for?
Who makes Comparator: placebo to sitagliptin?
What drug class is Comparator: placebo to sitagliptin in?
What development phase is Comparator: placebo to sitagliptin in?
What are the side effects of Comparator: placebo to sitagliptin?
What does Comparator: placebo to sitagliptin target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4 (dipeptidyl peptidase-4)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Comparator: placebo to sitagliptin vs similar drugs
- Pricing: Comparator: placebo to sitagliptin cost, discount & access